iPSC eye-cell transplant for late dry macular degeneration
Part of Eyes & vision clinical trials.
This Phase 1 study tests an experimental transplant made from your own cells to try to improve vision in people with advanced “late dry” age-related macular degeneration (AMD). It focuses first on safety, and may help some participants with limited central vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 50 to 75 years old
- You have advanced “late dry” AMD with specific damage in the center vision area (the fovea) and/or stubborn “wet” AMD that did not respond to standard treatment
- Your target eye’s vision (BCVA) is between 0.05 and 0.3 (so you still have some measurable vision but not normal vision)
- You are able to give informed consent and attend regular follow-up visits on schedule
- You are not relying on medications or conditions that increase bleeding, infection risk, or immune risk during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called Eyecyte-RPE™, made from special cells that support the retina. It is given as a single injection under the retina during eye surgery. The study aims to see if it can help people with advanced dry age-related macular degeneration (AMD) who have large areas of damage (geographic atrophy) in the center of their vision.
This early-phase study tests whether transplanting lab-made retinal cells from your own body can slow vision loss from geographic atrophy caused by dry age-related macular degeneration. It involves eye surgery and frequent follow-up to check safety and early signs of benefit.
This early-stage study tests whether a stem-cell–derived transplant to the back of the eye is safe and tolerable in people with dry age-related macular degeneration (AMD). If you qualify, you may receive the transplant and have close follow-up to watch for side effects.
This study tests a new treatment that uses your own stem cells to create retinal cells, which are then placed in your eye. The goal is to see if this can help improve vision for people with advanced age-related macular degeneration.
This trial tests a new stem-cell treatment for people with advanced dry age-related macular degeneration (AMD), a condition that causes blurring or loss of central vision. It aims to replace damaged cells in the back of the eye to potentially slow vision loss and improve day-to-day sight.
This trial tests a patch of retinal cells implanted under the retina to see if it can slow or stop vision loss from advanced dry AMD (geographic atrophy). It may help people whose central vision is already affected.
Hear when a new Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.